. Author manuscript; available in PMC: 2016 Jan 28.

Published in final edited form as: Lancet Respir Med. 2013 Aug 21;1(7):515–523. doi: 10.1016/S2213-2600(13)70166-8

Table 3.

Outcomes

	Haloperidol (n=71)	Placebo (n=70)	*Difference (95% CI)^ or RR (95% CI)**	P value
Alive, delirium free, and coma free days in first 14 days	5 (0-10)	6 (0-11)	−0.48 (−2.08, 1.21)	0.53
Days in delirium in first 14 days⁺	5 (2-8)	5 (1-8)	0.01 (−1.31 to 1.33)	0.99
Days in coma in first 14 days⁺	0 (0-2)	0.5 (0-2)	0.00 (−0.68 to 0.67)	0.99
Alive, delirium free, and coma free days in first 28 days	19 (0-24)	19.5 (0-25)	−0.26 (−3.72 to 3.46)	0.57
Days in delirium in first 28 days⁺	5 (2-10)	5 (1-9)	−0.38 (−2.37 to 1.62)	0.71
Days in coma in first 28 days⁺	0 (0-2)	1 (0-2)	−0.05 (−0.82 to 0.72)	0.90
Ventilator free days in first 28 days	21 (0-25)	17 (0-25))	0.25 (−3.26 to 4.16)	0.88
Mortality at 28 days	20 (28.2%)	19 (27.1%)	RR 1.04 (0.61 to 1.77)	..
Length of critical care stay (days) ^‡	9.5 (5-14)	9 (5-18)	−1.45 (−5.42, 2.52)	0.47
Length of hospital stay (days) ^§	18.5 (12-31)	26 (15-40)	−5.13 (−21.75 to 11.48)	0.54

Data are number (%), median (IQR), unless otherwise specified. RR=risk ratio.

CI bootstrapped.

†Including patients who died within study period.

^‡

Excluding patients who died in ICU: n=52 for haloperidol, n=51 for placebo.

^§

Excluding patients who died in hospital: n=42 for haloperidol, n=47 for placebo.